These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30777033)

  • 1. Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study.
    Manski-Nankervis JA; Thuraisingam S; Sluggett JK; Kilov G; Furler J; O'Neal D; Jenkins A
    BMC Fam Pract; 2019 Feb; 20(1):29. PubMed ID: 30777033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing for people with type 2 diabetes and renal impairment in Australian general practice: A national cross sectional study.
    Manski-Nankervis JE; Thuraisingam S; Sluggett JK; Lau P; Blackberry I; Ilomaki J; Furler J; Bell JS
    Prim Care Diabetes; 2019 Apr; 13(2):113-121. PubMed ID: 30262176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
    Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
    BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Technol Ther; 2016 Feb; 18(2):85-92. PubMed ID: 26752504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
    Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
    Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.
    Mahmoud F; Mullen A; Sainsbury C; Rushworth GF; Yasin H; Abutheraa N; Mueller T; Kurdi A
    Eur J Clin Invest; 2023 Aug; 53(8):e13997. PubMed ID: 37002856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.
    Kim J; Park S; Kim H; Je NK
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1723-1730. PubMed ID: 31475315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
    Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
    BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
    Huang H; Shetty S; Bauer E; Lang K
    Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program.
    Gadzhanova S; Pratt N; Roughead E
    Diabetes Res Clin Pract; 2017 Aug; 130():180-185. PubMed ID: 28646701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensification of medical management in type 2 diabetes: A real-world look at primary care practice.
    Zekarias K; Davey C; Seaquist E
    J Diabetes Complications; 2020 Jan; 34(1):107477. PubMed ID: 31711841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
    van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
    Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in medication utilization, glycemic control and outcomes among type 2 diabetes patients in a tertiary referral center in Singapore from 2007 to 2017.
    Tan YZ; Cheen MHH; Goh SY; Bee YM; Lim PS; Khee GY; Thumboo J
    J Diabetes; 2019 Jul; 11(7):573-581. PubMed ID: 30556375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.